[Systemic treatment of bladder cancer]
M Haas1, M Burger2, M J Schnabel2
1Klinik für Urologie, Universität Regensburg, Caritas Krankenhaus St. Josef, Landshuter Straße 65, 93053, Regensburg, Deutschland. maximilian1.haas@ukr.de.
Abstract:
Cisplatin-based chemotherapy regimens represent the standard of care in patients with locally advanced or metastatic urothelial carcinoma of the bladder. However, many patients are ineligible for cisplatin due to comorbidities or performance status. Immunotherapy with checkpoint inhibitors (CPI) has become a well-established treatment alternative in metastatic bladder cancer. The following review discusses current literature and guideline recommendations based on two case studies, in order to provide practical know-how about therapy sequences and treatment processes.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Treatment Resistant Cancers
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Infection IV: Nursing Management
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Kidney Transplant II: Surgical Procedure


